Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ESPR Esperion Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ESPR
Price (delayed)
$1.02
Market cap
$202.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.8
Enterprise value
$681.53M
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make
Highlights
Esperion Therapeutics's EPS has shrunk by 186% QoQ but it has increased by 18% YoY
ESPR's revenue is down by 22% since the previous quarter but it is up by 13% year-on-year
The net income has plunged by 196% from the previous quarter and by 77% YoY
The quick ratio has plunged by 58% YoY and by 21% from the previous quarter
Key stats
What are the main financial stats of ESPR
Market
Valuations
Earnings
Shares outstanding
198.2M
Market cap
$202.16M
Enterprise value
$681.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.63
Revenue
$259.57M
Gross profit
$169.51M
Operating income
-$39.96M
Net income
-$153.22M
EBIT
-$88.56M
EBITDA
-$88.48M
Free cash flow
-$100.35M
Per share
Balance sheet
Liquidity
EPS
-$0.8
EPS diluted
-$0.8
Free cash flow per share
-$0.51
Book value per share
-$2.15
Revenue per share
$1.32
TBVPS
$1.65
Total assets
$324.03M
Total liabilities
$750.24M
Debt
$594M
Equity
-$426.21M
Working capital
$47.81M
Debt to equity
-1.39
Current ratio
1.18
Quick ratio
0.72
Net debt/EBITDA
-5.42
Margins
Efficiency
Dividend
EBITDA margin
-34.1%
Gross margin
65.3%
Net margin
-59%
Operating margin
-15.4%
Return on assets
-45.9%
Return on equity
N/A
Return on invested capital
-16.2%
Return on capital employed
-166.9%
Return on sales
-34.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ESPR stock price
How has the Esperion Therapeutics stock price performed over time
Intraday
0.99%
1 week
-7.27%
1 month
29.06%
1 year
-53.21%
YTD
-53.64%
QTD
-29.17%
Financial performance
How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$259.57M
Gross profit
$169.51M
Operating income
-$39.96M
Net income
-$153.22M
Gross margin
65.3%
Net margin
-59%
The net income has plunged by 196% from the previous quarter and by 77% YoY
ESPR's operating margin has dropped by 194% since the previous quarter
The company's operating income has shrunk by 173% QoQ and by 15% YoY
Esperion Therapeutics's net margin has shrunk by 56% YoY
Price vs fundamentals
How does ESPR's price correlate with its fundamentals
Growth
What is Esperion Therapeutics's growth rate over time
Valuation
What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.63
Esperion Therapeutics's EPS has shrunk by 186% QoQ but it has increased by 18% YoY
The equity has decreased by 45% YoY and by 10% QoQ
The price to sales (P/S) is 77% lower than the 5-year quarterly average of 3.4 and 36% lower than the last 4 quarters average of 1.2
ESPR's revenue is down by 22% since the previous quarter but it is up by 13% year-on-year
Efficiency
How efficient is Esperion Therapeutics business performance
The return on invested capital has dropped by 200% year-on-year
Esperion Therapeutics's return on sales has shrunk by 182% YoY
The return on assets has declined by 37% year-on-year
Dividends
What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ESPR.
Financial health
How did Esperion Therapeutics financials performed over time
The total assets is 57% less than the total liabilities
The quick ratio has plunged by 58% YoY and by 21% from the previous quarter
The company's current ratio fell by 47% YoY and by 14% QoQ
The equity has decreased by 45% YoY and by 10% QoQ
ESPR's debt to equity is up by 26% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.